[HTML][HTML] Epstein–Barr virus and multiple sclerosis
SS Soldan, PM Lieberman - Nature Reviews Microbiology, 2023 - nature.com
Epstein–Barr virus (EBV) is a ubiquitous human lymphotropic herpesvirus with a well-
established causal role in several cancers. Recent studies have provided compelling …
established causal role in several cancers. Recent studies have provided compelling …
Epstein-Barr virus: Biology and clinical disease
B Damania, SC Kenney, N Raab-Traub - Cell, 2022 - cell.com
Epstein-Barr virus (EBV) is a ubiquitous, oncogenic virus that is associated with a number of
different human malignancies as well as autoimmune disorders. The expression of EBV viral …
different human malignancies as well as autoimmune disorders. The expression of EBV viral …
[HTML][HTML] The emerging landscape of immune cell therapies
Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …
immune cell therapies are among the most advanced, having already demonstrated …
[HTML][HTML] Epstein Barr virus: development of vaccines and immune cell therapy for EBV-associated diseases
X Cui, CM Snapper - Frontiers in Immunology, 2021 - frontiersin.org
Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated
in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated …
in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated …
Toxicities of chimeric antigen receptor T cells: recognition and management
JN Brudno, JN Kochenderfer - Blood, The Journal of the …, 2016 - ashpublications.org
Chimeric antigen receptor (CAR) T cells can produce durable remissions in hematologic
malignancies that are not responsive to standard therapies. Yet the use of CAR T cells is …
malignancies that are not responsive to standard therapies. Yet the use of CAR T cells is …
HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial
Importance Glioblastoma is an incurable tumor, and the therapeutic options for patients are
limited. Objective To determine whether the systemic administration of HER2-specific …
limited. Objective To determine whether the systemic administration of HER2-specific …
[HTML][HTML] Toxicity and management in CAR T-cell therapy
CL Bonifant, HJ Jackson, RJ Brentjens… - Molecular Therapy …, 2016 - cell.com
T cells can be genetically modified to target tumors through the expression of a chimeric
antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in …
antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in …
Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic …
I Tzannou, A Papadopoulou, S Naik… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Improvement of cure rates for patients treated with allogeneic hematopoietic stem-
cell transplantation (HSCT) will require efforts to decrease treatment-related mortality from …
cell transplantation (HSCT) will require efforts to decrease treatment-related mortality from …
Complete regression of metastatic cervical cancer after treatment with human papillomavirus–targeted tumor-infiltrating T cells
S Stevanović, LM Draper, MM Langhan… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Metastatic cervical cancer is a prototypical chemotherapy-refractory epithelial
malignancy for which better treatments are needed. Adoptive T-cell therapy (ACT) is …
malignancy for which better treatments are needed. Adoptive T-cell therapy (ACT) is …
[HTML][HTML] Therapeutic cancer vaccines
The clinical benefit of therapeutic cancer vaccines has been established. Whereas
regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in …
regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in …